FibroGen Appoints Maykin Ho, Ph.D., to Board of Directors
December 06 2018 - 4:00AM
FibroGen, Inc. (NASDAQ: FGEN), a leading biopharmaceutical company
discovering and developing a pipeline of first-in-class
therapeutics, today announced the appointment of Maykin Ho, Ph.D.,
as an independent director to FibroGen’s Board of Directors.
“We are delighted to welcome Dr. Maykin Ho, an accomplished
leader with a great breadth of knowledge in the biotechnology
industry, as a new Board member,” said Thomas B. Neff, CEO. “Dr. Ho
brings extensive experience in global strategy, finance, research,
and marketing, and she will be an invaluable advisor as we continue
to advance FibroGen’s multiple late-stage product programs, and
move closer to the potential commercialization of roxadustat.”
Dr. Ho has more than 30 years of experience in the healthcare
and finance industries. She serves on the boards of directors for
Agios Pharmaceuticals, Parexel International Corporation, the Aaron
Diamond AIDS Research Center, and the Institute for Protein
Innovation. Dr. Ho is also a venture partner of Qiming Venture
Partners and a member of the Biotech Advisory Panel of the Stock
Exchange of Hong Kong. She is a retired partner of the Goldman
Sachs Group where she served as senior biotechnology analyst,
co-head of healthcare for global investment research and advisory
director for healthcare investment banking. Prior to Goldman Sachs,
Dr. Ho held various managerial positions in licensing, strategic
planning, marketing and research at DuPont-Merck Pharmaceuticals
and DuPont de Nemours & Company. She was a postdoctoral
fellow at Harvard Medical School and a graduate of the Advanced
Management Program at The Fuqua School of Business, Duke
University. Dr. Ho received a Ph.D. in Microbiology and Immunology
and a B.S. from the State University of New York, Downstate Medical
Center.
"I have known and worked with the FibroGen team over the years,”
said Dr. Ho. "FibroGen continues to make progress on a diverse
pipeline and is poised to become a fully integrated company.
I am honored to join the Board at such an exciting time in the
company's growth and transformation."
About FibroGen FibroGen, Inc., headquartered in
San Francisco, California, with subsidiary offices in Beijing and
Shanghai, People’s Republic of China, is a leading
biopharmaceutical company discovering and developing a pipeline of
first-in-class therapeutics. The company applies its
pioneering expertise in hypoxia-inducible factor (HIF), connective
tissue growth factor (CTGF) biology, and clinical development to
advance innovative medicines for the treatment of anemia, fibrotic
disease, and cancer. Roxadustat, the company’s most advanced
product candidate, is an oral small molecule inhibitor of HIF
prolyl hydroxylase activity, completing worldwide Phase 3 clinical
development for the treatment of anemia in chronic kidney disease
(CKD), with a New Drug Application (NDA) currently under review by
the National Medical Products Administration (NMPA) in China. Our
partner Astellas submitted a NDA for the treatment of anemia in CKD
patients on dialysis in Japan and currently under review by the
Pharmaceuticals and Medical Devices Agency (PMDA). Roxadustat is in
Phase 3 clinical development in the U.S. and Europe and in Phase
2/3 development in China for anemia associated with myelodysplastic
syndromes (MDS). Pamrevlumab, an anti-CTGF human monoclonal
antibody, is advancing towards Phase 3 clinical development for the
treatment of idiopathic pulmonary fibrosis (IPF) and pancreatic
cancer, and is currently in a Phase 2 trial for Duchenne muscular
dystrophy (DMD). FibroGen is also developing a biosynthetic cornea
in China. For more information, please visit www.fibrogen.com.
Forward-Looking Statements This release
contains forward-looking statements regarding our strategy, future
plans and prospects, including statements regarding the development
of the company’s product candidates pamrevlumab and roxadustat, the
potential safety and efficacy profile of our product candidates,
and our clinical, regulatory plans, and those of our partners.
These forward-looking statements include, but are not limited to,
statements about our plans, objectives, representations and
contentions and are not historical facts and typically are
identified by use of terms such as “may,” “will”, “should,” “on
track,” “could,” “expect,” “plan,” “anticipate,” “believe,”
“estimate,” “predict,” “potential,” “continue” and similar words,
although some forward-looking statements are expressed differently.
Our actual results may differ materially from those indicated in
these forward-looking statements due to risks and uncertainties
related to the continued progress and timing of our various
programs, including the enrollment and results from ongoing and
potential future clinical trials, and other matters that are
described in our Annual Report on Form 10-K for the fiscal year
ended December 31, 2017, and our Quarterly Report on Form 10-Q for
the fiscal quarter ended September 30, 2018 filed with the
Securities and Exchange Commission (SEC), including the risk
factors set forth therein. Investors are cautioned not to place
undue reliance on these forward-looking statements, which speak
only as of the date of this release, and we undertake no obligation
to update any forward-looking statement in this press release,
except as required by law.
ContactFibroGen, Inc.Karen L.
BergmanVice President, Investor Relations and Corporate
Communications1 (415) 978-1433kbergman@fibrogen.com
FibroGen (NASDAQ:FGEN)
Historical Stock Chart
From Aug 2024 to Sep 2024
FibroGen (NASDAQ:FGEN)
Historical Stock Chart
From Sep 2023 to Sep 2024